Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

USRE47150E1 · kind E1 · reissue

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Zhuozhi Wang · Millbrae, US
• Junliang Pan · Moraga, US
• Joanna Grudzinska-Goebel · Berlin, DE
• Christian Votsmeier · Cologne, DE
• Jan Tebbe · Cologne, DE
• Joerg Birkenfeld · Frankfurt am Main, DE
• Nina Wobst · Wuppertal, DE
• Simone Brückner · Cologne, DE
• Susanne Steinig · Cologne, DE
• Peter Scholz · Cologne, DE

Key dates

• Filing date: Jul 12, 2016
• Grant date: Dec 4, 2018
• Expiry date: Jul 12, 2036

Classification

• Technology area (CPC —): General

Abstract

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.